Entinostat Neuroendocrine (NE) Tumor

Summary

This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE) tumors. Patients will continue on treatment until disease progression or intolerable toxicity occurs.

Timeline

Start

2017-12-13

Primary completion

2021-08-24

Completion

2021-10-06

Publications

• Jamison JK, Zhou M, Gelmann EP, Luk L, Bates SE, Califano A, Fojo T. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. Oncologist. 2024 Sep 6;29(9):817-e1213. doi: 10.1093/oncolo/oyae118.

Drugs

Indications